74.99

3.39% -2.63

After Hours: 75.10 0.11 +0.15%

Cvs Health Corp (CVS)

Overview News Price History Option Chain Financials Why CVS Down? Discussions Forecast Stock Split Dividend History

Cvs Health Corp stock is traded at $74.99, with a volume of 8.65M. It is down -3.39% in the last 24 hours and down -1.50% over the past month. CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It operates a top-tier health insurer (acquired through Aetna) through which it serves about 27 million medical members. The acquisition of Oak Street Health added primary care services to the mix, which could have significant synergies with all existing business lines.

Previous Close:

$77.62

Open:

$77.15

24h Volume:

8.65M

Relative Volume:

0.99

Market Cap:

$96.11B

Revenue:

$402.11B

Net Income/Loss:

$1.73B

P/E Ratio:

54.20

EPS:

1.3835

Net Cash Flow:

$7.81B

1W Performance:

-4.82%

1M Performance:

-1.50%

6M Performance:

-7.04%

1Y Performance:

+8.81%

1-Day Range:

$74.87

$77.44

1-Week Range:

$74.87

$79.56

52-Week Range:

$58.35

$85.15

Cvs Health Corp Stock (CVS) Company Profile

Name

Cvs Health Corp

Sector

Healthcare (1112)

Industry

Healthcare Plans (12)

Phone

(401) 765-1500

Address

ONE CVS DR., WOONSOCKET

Employee

300,000

Twitter

@cvshealth

Next Earnings Date

2026-02-10

Latest SEC Filings

CVS's Discussions on Twitter

Compare CVS vs UNH, CI, ELV, HUM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CVS Cvs Health Corp	74.99	99.48B	402.11B	1.73B	7.81B	1.3835
UNH Unitedhealth Group Inc	314.05	285.18B	447.57B	12.81B	16.08B	13.19
CI Cigna Group	268.63	71.87B	274.88B	6.29B	8.39B	22.19
ELV Elevance Health Inc	311.18	68.83B	199.13B	5.66B	3.17B	25.11
HUM Humana Inc	198.37	23.56B	129.66B	1.20B	375.00M	9.8083

Cvs Health Corp Stock (CVS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-12-26	Upgrade	Bernstein	Mkt Perform → Outperform
Oct-14-25	Initiated	Goldman	Buy
Aug-18-25	Upgrade	UBS	Neutral → Buy
Aug-14-25	Upgrade	Robert W. Baird	Neutral → Outperform
Feb-13-25	Upgrade	Leerink Partners	Market Perform → Outperform
Feb-12-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Jan-30-25	Upgrade	Edward Jones	Hold → Buy
Dec-03-24	Upgrade	Deutsche Bank	Hold → Buy
Nov-18-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-10-24	Upgrade	Barclays	Equal Weight → Overweight
Oct-04-24	Upgrade	TD Cowen	Hold → Buy
May-30-24	Initiated	Robert W. Baird	Neutral
May-07-24	Downgrade	TD Cowen	Buy → Hold
May-02-24	Downgrade	UBS	Buy → Neutral
May-01-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
May-01-24	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-06-24	Initiated	Barclays	Equal Weight
Feb-26-24	Initiated	Leerink Partners	Outperform
Dec-22-23	Initiated	HSBC Securities	Buy
Sep-19-23	Upgrade	Evercore ISI	In-line → Outperform
Sep-12-23	Upgrade	Wolfe Research	Peer Perform → Outperform
Aug-18-23	Downgrade	Edward Jones	Buy → Hold
May-26-23	Initiated	Piper Sandler	Overweight
Apr-21-23	Initiated	Cantor Fitzgerald	Overweight
Jan-03-23	Downgrade	Evercore ISI	Outperform → In-line
Nov-23-22	Resumed	Morgan Stanley	Overweight
Jun-17-22	Initiated	Loop Capital	Buy
May-27-22	Downgrade	Bernstein	Outperform → Mkt Perform
Mar-29-22	Downgrade	Deutsche Bank	Buy → Hold
Feb-11-22	Downgrade	Raymond James	Strong Buy → Outperform
Dec-14-21	Initiated	Goldman	Buy
Dec-01-21	Initiated	Seaport Research Partners	Buy
May-19-21	Initiated	Wells Fargo	Equal Weight
Mar-17-21	Downgrade	Guggenheim	Buy → Neutral
Jan-08-21	Upgrade	Jefferies	Hold → Buy
Sep-17-20	Initiated	Piper Sandler	Overweight
Jul-01-20	Initiated	SVB Leerink	Mkt Perform
May-14-20	Upgrade	Credit Suisse	Neutral → Outperform
Sep-27-19	Resumed	RBC Capital Mkts	Outperform
Sep-12-19	Initiated	Deutsche Bank	Buy
Jun-05-19	Upgrade	Standpoint Research	Hold → Buy
Apr-29-19	Downgrade	Credit Suisse	Outperform → Neutral
Apr-18-19	Initiated	Guggenheim	Buy
Apr-15-19	Downgrade	Oppenheimer	Outperform → Perform
Apr-10-19	Reiterated	BofA/Merrill	Buy
Mar-13-19	Initiated	Bernstein	Outperform
Feb-20-19	Downgrade	Wells Fargo	Outperform → Market Perform
Jan-17-19	Initiated	UBS	Buy
Dec-18-18	Initiated	Barclays	Overweight
Nov-29-18	Resumed	Goldman	Neutral
Nov-28-18	Initiated	Evercore ISI	Outperform
Oct-26-18	Resumed	Wolfe Research	Peer Perform
Jul-09-18	Upgrade	Citigroup	Neutral → Buy
Feb-27-18	Resumed	BofA/Merrill	Buy
Feb-13-18	Reiterated	Citigroup	Neutral

View All

Cvs Health Corp Stock (CVS) Latest News

05:23 AM